Engineered immune cells take aim at Hard-to-Treat ovarian cancer
NCT ID NCT07617753
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two cancer markers at once. It is for people with ovarian, peritoneal, or fallopian tube cancer that has come back or not responded to standard treatments. The therapy is personalized based on the patient's tumor markers to improve effectiveness and reduce the chance of cancer escaping the immune attack.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Metabolic clues: could your Body's energy use predict ovarian cancer outcomes?
- Can heated chemotherapy improve ovarian cancer outcomes?
- Can engineered immune cells target a common ovarian cancer protein?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a custom mRNA vaccine keep ovarian cancer from coming back?
- Experimental pill takes on Hard-to-Treat ovarian cancer